Cite
HARVARD Citation
McDermott, D. et al. (n.d.). 874PTreatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. Annals of oncology. p. . [Online].